July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Quantitative OCTA Change Analysis after 6 month Anti-VEGF Treatments for Proliferative Diabetic Retinopathy in the Real World
Author Affiliations & Notes
  • Jesse J Jung
    East Bay Retina Consultants, Inc., San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, California, United States
  • Michael H. Chen
    Silicon Valley Eyecare, California, United States
    Carl Zeiss Meditec Inc, California, United States
  • Quan V Hoang
    Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, New York, United States
    Ophthalmology, Singapore Eye Research Institute, Sinagpore National Eye Centre, Duke-NUS Medical School, Singapore
  • Footnotes
    Commercial Relationships   Jesse Jung, Carl Zeiss Meditec (F), Google Inc (C), Notal Inc (C); Michael Chen, Carl Zeiss Meditec (E); Quan Hoang, None
  • Footnotes
    Support  This work was supported in part by an unrestricted grant from Research to Prevent Blindness (RPB) and Career Development Awards from Research to Prevent Blindness (QVH) and K08 Grant (QVH, 1 K08 EY023595, National Eye Institute, NIH).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3009. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jesse J Jung, Michael H. Chen, Quan V Hoang; Quantitative OCTA Change Analysis after 6 month Anti-VEGF Treatments for Proliferative Diabetic Retinopathy in the Real World. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3009.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the effect of monthly anti-vascular endothelial growth factor (VEGF) treatment for proliferative diabetic retinopathy (PDR) on quantitative metrics of retinal microvasculature using optical coherence tomography angiography (OCTA).

Methods : Diabetes mellitus (DM) eyes with PDR treated with monthly anti-VEGF injections over 6 months from Jan. 2016-Dec. 2018 were included in this retrospective study. 3x3 mm OCTA scans with signal strength > 7 were acquired (Cirrus 5000 Angioplex, Carl Zeiss Meditec, Dublin, CA) at baseline and at 6 months. Automated segmented scans were averaged with registration for the superficial retinal layer. Quantitative parameters including 6-month interval change in the size and circularity of the foveal avascular zone (FAZ), parafoveal vessel density (VD) and perfusion density (PD) were analyzed. Univariate and multivariate linear regression with clustering on the individual level were performed to correlate quantitative metrics to baseline demographics.

Results : 19 eyes (14 patients, 10 male, 11 on insulin, 2 on hemodialysis (HD), mean age of 56 (range 40-77), mean HgbA1C 8.6 (±2.2)) were included. 5 had previous anti-VEGF, 1 had previous vitrectomy and 2 had previous PRP. 10 eyes had recurrence of PDR during follow-up, 4 of which required subsequent PRP but none required vitrectomy. Average overall follow-up was 54.0 months (±22.0) and eyes received an average of 9 (±4.4) injections during their entire follow-up.
Multivariate regression showed, when controlling for male gender and HD use, subjects with type 2 DM had a 1.83 (mm/mm2) lower interval change in the inferior ETDRS VD versus those with type 1 DM (p=0.017). Type 2 DM subjects also had less change in mean central (-1.19, p=0.044) and full mean (-1.77, p=0.0001) VD. When controlling for the confounding variable of male gender and presence of Type 2 DM, subjects on hemodialysis had a 1.83 lower change in inner inferior ETDRS VD (p=0.054). When controlling for presence of type 2 DM, subjects on HD had a 0.041 unit lower inferior ETDRS PD (p = 0.020). Subjects using insulin had a 0.13 mm2 lower change FAZ size (p=0.025).

Conclusions : After monthly anti-VEGF treatments over 6 months, preliminary findings suggest Type 2 DM, HD and insulin use may have a protective effect against changes in OCTA.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.